Statement by Mr. Nicolas Sarkozy, President of the Republic, on efforts in favor of research, particularly biomedical research, in Paris on June 10, 2011.

France Nicolas Sarkozy · President of France

10 June 2011 · 3rd international meetings on biomedical research · Paris, France

Context
Sarkozy addressed the 3rd International Meetings on Biomedical Research in Paris on June 10, 2011, outlining France's commitments to research and global health funding.
Main themes
Biomedical research, infectious diseases, AIDS/HIV, global health funding, France's research investment, malaria and tuberculosis, antibiotic resistance, public-private research partnerships, vaccine development, global solidarity in health
Duration
~23 min
72nd percentile
Words
2,767
72nd percentile
Sentences
162
83rd percentile
Readability
46
51st percentile
Grade
11.0
32nd percentile
Syntax
2.69
12th percentile
Vocabulary
2.30
73rd percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 32%31%
  • Social 28%28%
  • Institutional 16%15%
  • Ceremonial 15%15%
  • Geopolitical 6%6%
  • Technological 3%3%
  • Environmental 0%0%
  • Not in focus 1%

162 sentences in 74 paragraphs

Ladies and Gentlemen,

I am very pleased to be with you for the 3rd edition of the international meetings on biomedical research. This reflects my commitment to the development of research, particularly biomedical research. This meeting of major international and French industrialists with our public and private institutions, which I commend, is a very useful initiative that I support with all my strength.

This year, you have chosen the theme of infectious diseases. An immense concern for decision-makers around the world.

Indeed, 35 years ago, with the eradication of smallpox worldwide, one might have thought that we had managed to curb major epidemics. It was to forget that malaria remains endemic in many countries: 1 million deaths last year.

It was to forget that new infectious agents are constantly emerging.

June 4, 2011 marked the 30th anniversary of the observation of the first case of what would become AIDS.

A French team led by Luc MONTAGNIER and Françoise BARRÉ-SINOUSSI identified the virus in 1983.

This discovery earned them the Nobel Prize in 2008.

In 1982, an American team identified the prion, which would be held responsible for the epidemic of Creutzfeldt-Jakob disease at the end of the 1990s.

I will not teach you anything, specialists that you are, but I am struck by the fact that respiratory infections still cause 3 million deaths each year, infectious diarrhea causes 2.5 million deaths each year, measles, for which there is a vaccine, causes 750,000 deaths each year. We also know that at least one-third of cancers, cervical and head and neck cancers, are linked to infectious agents.

Diseases like tuberculosis, which we believed to be eradicated, are reappearing in our latitudes.

Antibiotic resistance is only growing, and you must constantly invent new responses.

And current events remind us of this every day: infectious diseases are part of our daily lives.

I think of the H5N1 flu epidemic, the Chikungunya epidemic, and of course the bacterial foodborne illnesses that have been affecting Europe for the past few days.

With globalization and increased travel, the issue of infectious diseases has become even more pressing.

We cannot afford to let up our efforts.

France must be present at the rendezvous of international solidarity. Malaria, tuberculosis, and AIDS dramatically affect developing countries, particularly sub-Saharan African countries.

And despite a financial context that you know is constrained, France will do its duty.

Last September, at the UN Summit, I announced that France would not only maintain its participation in the Global Fund to Fight AIDS, Tuberculosis, and Malaria, but that it would increase its participation by 20%. I do not know if you realize the political choice that this represents to increase by 20% the funds we allocate even as we are reducing our budget. France will thus remain the second largest contributor to the Fund, behind the United States, with 360 million euros. It is our responsibility.

The crisis slows growth, decreases our tax revenues, but not the epidemics. There is no reason to let our guard down.

My wife and I are particularly committed to the fight against AIDS. We know that major progress is being made every day.

While the development of a vaccine and a curative treatment remain priority objectives, we must relentlessly strengthen our prevention efforts against HIV.

Recent studies have shown the preventive effectiveness of antiretrovirals, particularly in the fight against mother-to-child transmission.

AIDS — it must be said — still kills 1.8 million people each year, including 250,000 children. Professor DELFRAISSY, you will allow me to quote you because it struck me, you said: "AIDS has been the major epidemic of the 20th century and remains that of the 21st."

In 30 years, you have made considerable progress in the fight against HIV. Thanks to all of you, thanks to the community of researchers, we can hope that the 21st century will be the one of victory, the victory of research against AIDS.

Building the future means giving researchers the means to work, to progress, and to innovate. I have committed to making biomedical research the top priority of our research. The French place great importance on their health.

We devote nearly 12% of our national wealth to health expenditures. Health insurance is one of the pillars of our social model. Being able to ensure quality care for the French means supporting the relentless efforts of researchers as well as those of industrialists.

Last year, we made a mutual commitment to report on our respective actions.

Your record is particularly fruitful. 28 million euros in research contracts have been signed to date based on more than 150 constructive and structuring exchanges initiated since our first meeting in 2009. In addition to more than twenty contracts that are in very advanced negotiation phases. I want to congratulate you on this.

Encouraging scientific excellence, rewarding the risk-taking of courageous and enterprising industrialists is the very essence of the action I want to lead and that I have been leading since 2007. For four years, my responsibility has been to ensure that France can regain a competitive, job-creating, prosperous economy. An economy that can finance our social model. To do this, we needed to give French universities the means to achieve their ambitions. That is what we have done with Valérie PÉCRESSE.

Institutional means first. Today, French universities are autonomous, like all major universities in the world. They can forge partnerships, attract the best researchers and teachers, and compete on equal terms with their competitors. Today this seems obvious, it seems simple, but before 2007, uttering the word autonomy was a guarantee of blockage.

Financial means as well, in the context I indicated. Since 2007, the state's effort for higher education and research — hold on, it's simple — we are increasing this effort by one billion euros per year, including in 2009 when France's tax revenues decreased by 22%. The year when France's tax revenues decreased by 22%, we increased the means for higher education and research by one billion euros, and we continue every year.

But in our country, for 30 years, we had developed the bad habit of sacrificing investment and prioritizing the short term.

The crisis has shown that this strategy was at the end of its rope. Not only was France spending too much, but above all, France was spending poorly.

We have therefore decided on a different strategy. We must think about the jobs and companies of tomorrow.

We launched a 35 billion euro Future Investments plan in the midst of the crisis. And I still remember the controversy that my remarks sparked: "How can you — they said to me — explain that France is too indebted and at the same time launch a 35 billion euro investment plan!" Because the question is not debt, the question is what we do with that debt. If we go into debt to invest, we create wealth. If we go into debt to pay recurring operating expenses, we prepare for poverty and crisis. The General Commissioner for Investment, René RICOL, is responsible for implementing this plan.

20 billion euros are allocated to higher education and research. 20 billion euros. You know, when we compare ourselves to neighboring European countries, I see the cuts that have been made to these budgets, particularly on the other side of the Channel. I do not presume to judge; I simply say, look at the difference in policy, we will see which one ultimately yields the best results. I insisted that projects be selected based on criteria of excellence — excellence is not a dirty word. Not everyone can have the same resources — and the selection is made by very high-level international juries. I am well aware of this revolution. But it was unavoidable and inevitable.

The field of Health and Biotechnology will therefore benefit from 2.5 billion euros in investments. One billion euros has already been allocated to 74 projects in areas that are at the heart of the health challenges of our time: obesity and diabetes, neuroscience, and your current concern, infectious diseases.

The fight against infectious diseases is one of the areas where the effort of Future Investments is the most significant. The POLMIT hospital-university institute project at the University of the Mediterranean, dear Yvon BERLAND, is thus one of the 6 new IHUs whose list we have recently finalized.

Not everyone can be an IHU. The center of excellence lifts everyone up, and we must accept that. Equality is not egalitarianism. It is a very strong idea. Equality is giving more to those who deserve it, more to those who may have disadvantages, more to those who are the most excellent. To lift everyone up.

It will be dedicated to infectious and tropical diseases. Led by Didier RAOULT, it will receive more than 72 million euros in funding.

The IHUs will be linked to scientific cooperation foundations and will have the necessary means and autonomy for their development. France will thus be able to compete with the best biomedical research centers in the world. Thanks to these IHUs, the alliance between research excellence, care excellence, and economic valorization will be ensured; economic valorization, again, is not a dirty word, it is not incongruous. Research is not distorted by economic valorization; it is extended by economic valorization.

In total, the IHUs will receive a funding of 850 million euros. I apologize for all these figures, but if they were figures in the negative, you would reproach me; these are figures in the positive.

The Lyon-Pasteur technological research institute, dedicated to biomedical innovation in infectious diseases, is also one of the first 6 labeled IRTs.

In addition, several laboratories engaged in the fight against infectious diseases have received the label of Laboratory of Excellence. If you knew the satisfaction it represents for me to be able to use the word excellence without causing a collapse of the entire system.

Now we have the right to talk about excellence; do not imagine the change that this represents. Well, there are other words that we still cannot pronounce, but excellence, remember? Pronounce this word, as it is your daily life. It was something astonishing.

In these laboratories of excellence, there is the Vaccine Research Institute of the University of Paris XII working on a vaccine against HIV and hepatitis C, or the laboratory on emerging infectious diseases at the Pasteur Institute. Others are working on the link between cancer and infectious diseases.

In all fields of research on infectious diseases, French researchers are present and active. I want to commend the remarkable results of the research teams in infectious diseases from the now autonomous universities. These teams represent 12% of French forces in biology and health but 20% of the best publications!

I also want to commend the work of the Alliance of Life and Health Sciences.

Its president, André SYROTA, who coordinates at my request the strategic action and national management of research organizations in life sciences.

The laboratories of excellence in our universities must also be able to rely on dynamic companies and SMEs in the life sciences sector.

We need this cooperation between universities and companies. Here too, I am very happy; we can say this without being accused of the commercialization of the university or the arrival of capitalism in universities. What do we do with this alliance between universities and companies? We develop solutions to combat resistance to antimicrobial agents, we develop new treatments for certain cancers, we develop antibacterial agents, particularly against severe and difficult-to-treat infections.

To support this dynamic, Future Investments provide for 900 million euros in capital allocation for Technology Transfer Acceleration Companies. The jury has already labeled 5 projects. These 5 projects make life sciences and health one of their priorities.

This was the missing link in valorization in our country.

Professional teams will offer a single point of contact for researchers in the early phases where private investors are still relatively rare and quite cautious.

The state is fully in its role by intervening at this critical stage of industrial application. Between talented researchers and innovative companies, the state must be present to facilitate and take risks when the private sector needs a little encouragement.

For four years, we have significantly strengthened the resources available for health research. We have improved coordination among the stakeholders involved throughout the innovation chain. Where there were barriers, there is now dialogue and cooperation.

I am aware that we still need to make progress. As we did for the Alzheimer Plan, we must do better to involve the vibrant forces of the nation in our common goal: to preserve the treasure that is our health.

I think of large corporate foundations, patient associations, and players from the industrial and service sectors, who, in the proximity of the daily lives of the French people, are eager to act and engage alongside you.

For the fight against obesity, which unjustly affects nearly 20% of children, often in the least advantaged social categories.

For the fight against rare diseases, which blindly strike so many French families. While they are individually rare, they are collectively so frequent: 3% of births, and it can happen to any one of us!!!

Therefore, I ask Valérie PÉCRESSE, Xavier BERTRAND, and Nora BERRA, as well as the Alliance around André SYROTA, to involve all talents and good wills in their efforts.

I ask them to finalize the creation of a Foundation for scientific cooperation, which could bring together research organizations, universities, and university hospitals. For this Foundation to operate in the most effective way, I especially dream that it includes actors from the daily lives of the French people. I know that some large companies are already eager to engage alongside you. In the coming months, I am counting on you to gather these energies in service of the health of the French people.

In calling for the creation of this new Foundation, it is not about taking control of anyone or anything!

Nor is it about replacing the foundations being created in autonomous universities. They must come to fruition.

It is also not about adding a layer of complexity to a system that we want to simplify.

It is only about uniting good wills. Simplifying the landscape and replacing the countless Scientific Interest Groups (GIS) created over the years whenever it was necessary to coordinate public action and private action.

I have long been convinced that life sciences and health are major assets for the growth of our country.

You see, ladies and gentlemen, France is changing, it had to change, and it must continue to change because the world is changing, and the world will not wait for us. I would like the international research laboratories represented here today to realize how profoundly we have changed the conditions for welcoming investments in our country—with the Research Tax Credit and the elimination of the professional tax.

Let them see how effective our research teams are. How the awarding of contracts is now simplified, accelerated, and professionalized.

How determined we are to continue and amplify our action.

French public action does not weaken; it will amplify. The first results are here. Your laboratories, your teams, your ideas are an opportunity for France. You are welcome in our country.

All the actions we are taking aim to give you the means to work and innovate, and if there were any doubts about this, my determination to continue the action we have initiated is total, total. And if I have one regret, it is that I feel we are not moving fast enough, and if I have one regret, it is that we have not yet done enough, and if I have one regret, it is that I have not convinced enough people that time does not belong to us, that we do not have time, that there is the urgency of a world moving at a staggering speed, and no one can blame the President of France for wanting France to be well in its century, the 21st, and not remain in the previous one, the 20th. We have changed centuries, we have changed worlds, it is an opportunity, and the old divides and old oppositions make no sense. It is the past, a past much further away than one might imagine. These are debates from another time. Today, you need resources, we are providing them, reforms we are implementing. And I hope you will share the same enthusiasm, the same determination, and that you will achieve the same excellence, the results that you have already brought us.

Thank you for your attention.